Test efficaciousness of a number of potential stoichiometric and catalytic enzymes as pretreatments against the toxcity of chemical warfare nerve agents in vivo in animal models.

The US Army Medical Research Acquisition Activity (USAMRAA) has a procurement requirement for the US Army Medical Research Institute of Chemical Defense (USAMRICD) at Aberdeen Proving Grounds, MD 21010. The strategy is to award a firm-fixed-price contract over a 36 month time frame consisting of six 6-month ordering periods; a base period and 5 optional periods. The authority cited is Federal Acquisition Regulation (FAR) 13.106-1(b). This is a follow-on requirement for commercially available purified recombinant adenoviruses directly related to previous work completed by Welgen Incorporated, 100 Barber Avenue, Worcester MA. The follow-on protocol requires the same work and results for contunity of on-going research and for the research to contiune without break in performance. To award to a new vendor could jeopardize the protocol by receiving different results due to process differences. A solicitation SF 1449 will not be provided. If any companies can meet the Government's above need, a capabilities statement can be sent to Erin Maddox at erin.maddox@amedd.army.mil. This serves as the Government's intent to award a sole source to ensure the research mission at USAMRICD is not comprimised. If no responses are received by 8:00 am eastern standard time on 5 June 2012, the strategy will commence.